P2P review · IL-17A inhibitor
Secukinumab (Cosentyx) P2P review prep
IL-17A inhibitor. Indications: Psoriasis, PsA, AS
Drug class
IL-17A inhibitor
Payer criteria typically applied
- Disease severity
- Failed prior systemic
Common medical director objections
- Psoriasis BSA ≥10% or PASI
- Step therapy through TNFi typically
Pitfalls to avoid
- TNFi failure required
Frequently asked questions
What does the payer typically require for Secukinumab (Cosentyx)?
Disease severity; Failed prior systemic.
What objections does the medical director typically raise?
Psoriasis BSA ≥10% or PASI; Step therapy through TNFi typically.
What pitfalls should I avoid during the P2P call?
TNFi failure required.
Sources
Prep Secukinumab (Cosentyx) P2Ps faster — try ApprovalHelp free
ApprovalHelp auto-prepares P2P talking points from the patient's chart, surfaces payer-specific objections, and generates the post-call appeal draft. no setup fee.
Get started →Contact: hello@approvalhelp.com